Text Size
   
Activery : amorphous drugs, amorphization and particle production
  • Activery
    • Who we are
      • Drug life-cycle management
      • Activery background
    • Technology
    • Contact us
    • R&D locations
    • GMP Plant
    • Site Map
      • Pharma news and events
  • Amorphous drugs and amorphization
    • Why amorphous drugs
    • Stable amorphous drug
    • Amorphous vs crystalline drug
    • Patenting amorphous forms
  • Micro and nanoparticles
    • Particle sizing in drugs
    • Crystalline particles
    • Biovailability enhancement
    • Solubility improvement
    • Patenting particle size distribution
  • Products and projects
    • Combination products
    • Powder for inhalation
    • Oncology targetting
  • Solid State Development
    • Solid state analytical services
    • Amorphization consultancy
    • Amorphous Market & IP Inteligence
Tuesday 06 January

07:36:13

Activery in pulmonary delivery

Activery in pulmonary delivery

Acivery has developed a new process for the production of pharmaceutical actives for pulmonary drug. Our technology leads to the precipitation of non-agglomerated crystalline powders with narrow particle size distributions  

Creating new paths to differentiated medicines

Creating new paths to differentiated medicines

In Activery we believe that solid state modifications may lead to a critical changes in your active pharmaceutical, thus to a differentiated drug or to a brand new innovative medicine  

Activery, the solid state specialist

Activery, the solid state specialist

Activery possess unrivalled specialist expertise about different crystallization techniques and expert knowledge in the field of solid state modulation.  

Particles and nanoparticles for special uses

Particles and nanoparticles for special uses

In Activery, we design and produce particles for special uses where size matters such as nanoparticles for cancer treatment. Through our technology you would enable new administration routes or renewed performance of your drug formulation.  

Contact us

Activery Locations
Phone: +34 935 820 152
Fax: +34 935 801 354
E-mail: contactus @ activery.com

R&D facilities
Centre d'empreses de noves tecnologies
Parc Tecnològic del Vallès
08290 Cerdanyola del Vallès
Barcelona
Spain


Head office

Avda Carlos III, 36 1 Derecha
Pamplona 31003
Navarra

R&D Facilities PDF Print E-mail

Our understanding and expert knowledge in the field of particle design, solid-state control and supercritical fluid technologies, enables us to take the right steps right away to achieve your goals.

 

We work together with our clients to rapidly obtain the results they need by using a pragmatic go/no go approach.

 

R&D Activery Locations

Phone: +34 935 820 152

Fax: +34 935 801 354

E-mail: contactus @ activery.com

R&D facilities

 

Centre d'empreses de noves tecnologies

Parc Tecnològic del Vallès 08290

Cerdanyola del Vallès Barcelona Spain

Next >
 

Pharma Notes

  • Orion files US suit to protect Stalevo drug.
  • New R&D strategies and role of Spin-offs speed pharmaceutical product development
  • Patent infringement can also occur by submitting an Abbreviated New Drug Application (ANDA) to the Food and Drug Administration (FDA)
  • New combination for rheumatoid arthritis: tocilizumb with methotrexate
  • Patients who took Crestor were half as likely to have heart attacks, strokes or operations to open clogged arteries

Solid State Events

  • Activery at the annual Generics conference
  • Pharmaceutical co-crystals
  • Amorphous Pharmaceutical Materials
  • Contact us
  • Sitemap
  • Pharma News
  • News in amorphous drugs
  • Events in solid state
  • Pharmaceutical market news
Activery : amorphous drugs, amorphization and particle production